The FDA based its decision on clinical data from the Phase 2/3 EPIC-HR trial, which enrolled non-hospitalized adults aged 18 and older with confirmed COVID-19 who are at increased risk of progressing to severe illness.
Pfizer Inc. announced that the U.S. Food and Drug Administration has authorized the emergency use of PAXLOVID™ for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.laboratories, which was specifically designed to block the activity of the SARS-CoV-2 M^pro, an enzyme that the coronavirus needs to replicate.
The data demonstrated an 89% reduction in the risk of COVID-19-related hospitalization or death from any cause in adults treated with PAXLOVID, compared to placebo, within three days of symptom onset . No deaths occurred in the treatment group compared to nine deaths in the placebo group by Day 28. While PAXLOVID clinical trials did not include patients under the age of 18, the authorized adult dosing regimen is expected to result in comparable blood concentration levels of PAXLOVID in pediatric patients 12 years of age and older weighing at least 40 kg.
With PAXLOVID now authorized for emergency use, Pfizer stands ready to start delivery in the U.S. immediately. In November 2021, Pfizer announced an agreement with the U.S. government to supply 10 million treatment courses of PAXLOVID, with delivery fulfillment expected to be completed in 2022.In addition to the U.S.
Philippines Latest News, Philippines Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
No COVID-19 vaccinations in Antipolo and Cainta during Yuletide seasonAntipolo City and the Municipality of Cainta in Rizal announced on Thursday, Dec. 23, that they are suspending their COVID-19 vaccination activities as the Christmas season draws near.
Read more »
PH slightly climbs from bottom of Bloomberg COVID-19 resilience rankingThe Philippines has finally moved up from the bottom spot in the latest Bloomberg COVID-19 resilience ranking, as eased restrictions, improved vaccination and lower positivity rates suggest “undetected infection is finally coming under control.”
Read more »
Philippines approves Pfizer's COVID-19 vaccine for 5 to 11 years oldThe Philippine Food and Drug Administration (FDA) has approved the emergency use authorization (EUA) for Pfizer-BioNTech's COVID-19 vaccine for ages 5 to 11 years old.
Read more »
WHO chief says blanket vaccine booster programs may prolong COVID-19 pandemicBlanket vaccine booster programs are likely to prolong the COVID-19 pandemic rather than ending it, as a result of unequal distribution of vaccines between rich and poor countries, the head of the World Health Organization (WHO) warned on Wednesday.
Read more »
PH eyes 'barangay-to-barangay’ COVID-19 vaccinationGovernment will roll out barangay-to-barangay COVID-19 vaccinations to reach millions who have yet to get a single coronavirus jab.
Read more »
DOH cuts COVID-19 booster shot interval to three monthsMANILA — The Department of Health on Tuesday halved the wait time for a COVID-19 vaccine booster to three months to help prevent the spread of the more
Read more »